Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2020-02-04 Regulatory Filings
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Clarification to announcements of 3 February 2020 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement providing clarifications to previous announcements made on 3 February 2020. It addresses specific details about a service agreement term and corrects a previous statement about share options. The document is short (2025 characters) and does not contain financial statements, detailed financial data, or comprehensive report content. It is not a full report but rather a regulatory announcement clarifying prior information. There is no indication that this is a report publication announcement or a certification. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2020-02-04 English
Invion signs R&D Services Agreement with Pavay Biotech 2 pages 251.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement about Invion Group signing a services agreement with Pavay Biotech. It details the terms of the R&D services agreement, fees, and background information about the companies involved. There is no financial data, no mention of quarterly or annual results, no voting results, no management changes, no legal proceedings, and no regulatory certifications. The document is a corporate announcement about a business agreement and partnership, which fits best under Capital/Financing Update (CAP) as it relates to a new business contract and ongoing service fees, indicating a financing or capital-related update rather than a full report or other category. The document length is under 5,000 characters and is not a report publication announcement or certification. Therefore, the best classification is CAP with high confidence.
2020-02-02 English
Lapse of unlisted share options 1 page 229.0KB
Transaction in Own Shares Classification · 95% confidence The document is an ASX announcement regarding the lapse of unlisted share options following the retirement of former directors. It provides specific details about the options lapsed and those remaining on issue. The content is focused on share options status and does not contain financial statements, management discussion, or regulatory certifications. It is not a full report, earnings release, or management report. It is an announcement related to share capital instruments but does not indicate new share issuance or capital changes like stock splits. The closest fitting category is 'Transaction in Own Shares' (POS), which covers reports of share repurchases or issuance activities, including share options lapsing or changes in share capital instruments. Given the document length and content, the classification is POS with high confidence.
2020-02-02 English
Appendix 4C - December 2019 quarter 5 pages 1.0MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities for the quarter ended 31 December 2019. It includes actual financial data such as receipts, payments, cash balances, and reconciliations. The document also contains a compliance statement and notes related to accounting standards. The presence of substantive financial data for a quarter and the format consistent with a quarterly cash flow report indicates this is an Interim / Quarterly Report. It is not an announcement or a brief summary but a full quarterly cash flow report as required by ASX Listing Rules. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q4 2019
2020-01-29 English
Appendix 4C December 2019 - cover note and market update 2 pages 86.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C - QUARTERLY CASH FLOW REPORT' and provides a detailed quarterly cash flow report along with a market update for the December 2019 quarter. It includes substantive financial data such as cash position movements, funding status, and business progress updates. The document is approximately 4446 characters long, which is sufficient to contain detailed financial and operational information. The content focuses on quarterly financial results and operational updates rather than just announcing or linking to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2020
2020-01-29 English
App 3Z - Campbell - correction to date ceased to be director 2 pages 212.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the cessation date of a director and the director's relevant interests in securities, including direct and indirect holdings. This type of document is a formal notification of personal share transactions or interests by a company director. It does not contain financial performance data, audit information, or management discussion. It is not an announcement of a report but a regulatory disclosure about director shareholdings. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on director interests, confirming this classification with high confidence.
2020-01-08 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.